WO2013035641A1 - ブロック共重合体の製造方法 - Google Patents
ブロック共重合体の製造方法 Download PDFInfo
- Publication number
- WO2013035641A1 WO2013035641A1 PCT/JP2012/072160 JP2012072160W WO2013035641A1 WO 2013035641 A1 WO2013035641 A1 WO 2013035641A1 JP 2012072160 W JP2012072160 W JP 2012072160W WO 2013035641 A1 WO2013035641 A1 WO 2013035641A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- block copolymer
- reaction
- general formula
- pasp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/3311—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group
- C08G65/3314—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic
- C08G65/3315—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic aromatic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33331—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group
- C08G65/33334—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group acyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/40—Polyamides containing oxygen in the form of ether groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
- C08G73/10—Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
- C08G73/14—Polyamide-imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
- C08G73/10—Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
Definitions
- the present invention relates to a micelle preparation containing a block copolymer and a drug using the same, and further to a method for producing a block copolymer in an anticancer agent containing the micelle preparation as an active ingredient.
- Drugs especially anticancer drugs, are often hydrophobic compounds that are hardly soluble in water. In order to obtain a desired therapeutic effect using such a drug, the drug is usually solubilized and administered to a patient. Therefore, solubilization of poorly water-soluble drugs, particularly poorly water-soluble anticancer agents, is important in oral or parenteral preparations, particularly intravenous preparations.
- Patent Document 1 Patent Document 2, or Patent Document 3 describes a method using a block copolymer that forms micelles as a drug carrier.
- Patent Document 4 Patent Document 5 and Patent Document 6 describe paclitaxel-encapsulated micelles using a block copolymer having a polyethylene glycol (PEG) structure portion and a polyamino acid structure portion as a drug carrier.
- PEG polyethylene glycol
- Patent Document 5 discloses that a paclitaxel-encapsulated micelle having a high antitumor effect can be obtained by converting the structure of the polyamino acid structure portion of the block copolymer forming the micelle used in Patent Document 4. Are listed.
- Patent Document 6 the residual carboxylic acid structure in the structure of the polyamino acid structure portion of the block copolymer that forms micelles by a production method different from Patent Document 5 is reduced, and the paclitaxel-encapsulated micelle described in Patent Document 5 It is described that the toxicity is reduced in comparison.
- PEG-pAsp (polyaspartic acid) -Ac produced by the method described in Patent Document 2 may be substituted with an aryl ( C1-C8)
- An alkyl alcohol is introduced and the product is isolated. Thereafter, introduction of a urea transfer form of pAsp and a cyclization reaction are performed to reduce the residual carboxyl group of pAsp.
- the aryl (C1 to C8) alkyl alcohol which may have a substituent is partially eliminated by this second stage heating reaction.
- Patent Document 5 As a result of intensive studies to solve the above problems, the present inventors have surprisingly found that, in the method for producing a block copolymer described in Patent Document 5, by applying specific limited reaction conditions, Patent Document The manufacturing method by the one pot of the block copolymer of 6 was discovered. Furthermore, the difficulty in production was solved and the present invention was completed.
- R1 represents a hydrogen atom or a (C1 to C5) alkyl group
- R2 represents a (C1 to C5) alkylene group
- R3 represents a methylene group or an ethylene group
- R4 represents a hydrogen atom or (C1 to C4)
- n represents 20 to 500
- x represents 0 to 100
- y represents 0 to 100.
- the sum of x and y is 2 to 200.
- R1 represents a hydrogen atom or a (C1 to C5) alkyl group
- R2 represents a (C1 to C5) alkylene group
- R3 represents a methylene group or an ethylene group
- R4 represents a hydrogen atom or (C1 to C4)
- R5 represents a hydroxyl group
- C3-C6) may be substituted with a cyclic alkyl group or a tertiary amino group (C1-C5) represents an alkyl group).
- n 20 to 500
- m 2 to 200
- a 0 to 100
- b 0 to 100.
- the sum of a and b is not less than 1 and not greater than m.
- the proportion of R5 being a hydroxyl group is 0 to 5% of m
- the proportion of optionally substituted aryl (C1 to C8) alkoxy groups is 10 to 80% of m
- —N (R6 ) —CO—NHR7 is 11-30% of m] It is a manufacturing method of the block copolymer represented by these.
- R1 is a methyl group
- R2 is a trimethylene group
- R3 is a methylene group
- R4 is an acetyl group
- n is 80 to 400
- m is 15 to 60
- a is 5 to 60
- b is 5 to 60 It is a manufacturing method of the block copolymer as described in 1).
- the reaction temperature in the production method described in Patent Document 5 is strictly controlled, and the carbodiimide compound is converted into the amount of the carboxyl group (x and y in the general formula (2)).
- the block copolymer described in Patent Document 6 is obtained instead of the block copolymer described in Patent Document 5. That's it.
- the production method of the block copolymer of the present invention can adjust the introduction rate of the aryl (C1 to C8) alkyl alcohol optionally having a substituent into the compound represented by the general formula (2). This is because once introduced aryl (C1-C8) alkyl alcohol does not leave by cyclization as in the production method described in Patent Document 6, and free aryl (C1-C8) alkyl alcohol in the reaction solution does not increase. It depends. As a result, the number of unreacted carboxyl groups of pAsp of the compound represented by the general formula (2) can be surely reduced. Therefore, as compared with the production method described in Patent Document 6, the production method of the block copolymer of the present invention is an industrially excellent production method in which the production of the product can be easily controlled by a one-step reaction.
- the present invention provides the following general formula (2) having a polyethylene glycol (PEG) structure portion and a polyamino acid structure portion, wherein R1 represents a hydrogen atom or a (C1 to C5) alkyl group, and R2 represents (C1 to C5).
- R1 represents a hydrogen atom or a (C1 to C5) alkyl group
- R2 represents (C1 to C5).
- R3 represents a methylene group or an ethylene group
- R4 represents a hydrogen atom or a (C1-C4) acyl group.
- n represents 20 to 500
- x represents 0 to 100
- y represents 0 to 100.
- the sum of x and y is 2 to 200.
- Each numerical value is an average value.
- R5 Represents a hydroxyl group, an aryl (C1 to C8) alkoxy group optionally having substituent (s) or —N (R6) —CO—NHR7 (wherein R6 and R7 may be the same or different, (C3 ⁇ C6) Cyclic Alky It may be substituted with a group or tertiary amino group showing a (C1 ⁇ C5) alkyl group).
- n 20 to 500
- m 2 to 200
- a 0 to 100
- b 0 to 100.
- the sum of a and b is not less than 1 and not greater than m.
- the proportion of R5 being a hydroxyl group is 0 to 5% of m
- the proportion of optionally substituted aryl (C1 to C8) alkoxy groups is 10 to 80% of m
- —N (R6 ) —CO—NHR7 is 11 to 30% of m].
- examples of R1 include a hydrogen atom or a (C1-C5) alkyl group, and a (C1-C5) alkyl group is preferable.
- Specific examples of the (C1 to C5) alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a s-butyl group, a t-butyl group, and an n-pentyl group.
- a methyl group is particularly preferable.
- (C1 to C5) alkylene group for R2 include a methylene group, an ethylene group, a trimethylene group, a tetramethylene group, and the like, and an ethylene group and a trimethylene group are preferable.
- R3 includes a methylene group or an ethylene group, and a methylene group is preferable.
- R4 includes a hydrogen atom or a (C1-C4) acyl group, preferably a (C1-C4) acyl group, and specifically includes a formyl group, an acetyl group, a propionyl group, a butyroyl group, and the like. Is particularly preferred.
- n is 20 to 500, preferably 80 to 400, x is 0 to 100, preferably 5 to 60, y is 0 to 100, preferably 5 to 60, x The sum of y and y is 2 to 200, preferably 10 to 100, particularly preferably 5 to 60.
- the aryl (C1 to C8) alkoxy group in R5 is a straight chain or branched chain (C1 to C8) to which an aromatic hydrocarbon group such as a phenyl group or a naphthyl group is bonded.
- C8 An alkoxy group is mentioned.
- benzyloxy group, phenethyloxy group, phenylpropoxy group, phenylbutoxy group, phenylpentyloxy group, phenylhexyloxy group, phenylheptyloxy group, phenyloctyloxy group, naphthylethoxy group, naphthylpropoxy group, A naphthyl butoxy group, a naphthyl pentyloxy group, etc. are mentioned.
- Examples of the substituent in the aryl (C1 to C8) alkoxy group which may have a substituent include a lower alkoxy group such as a methoxy group, an ethoxy group, an isopropoxy group, an n-butoxy group and a t-butoxy group, a fluorine atom , Halogen atoms such as chlorine atom and bromine atom, nitro group, cyano group and the like. Substituents in which the number of substitutions of the substituent is from 1 to the maximum number that can be substituted, and in all substitutable positions are included in the present invention, but unsubstituted is preferred.
- Examples of the optionally substituted aryl (C1 to C8) alkoxy group include unsubstituted phenyl (C1 to C6) alkoxy groups.
- Examples thereof include an unsubstituted benzyloxy group, an unsubstituted phenethyloxy group, an unsubstituted phenylpropoxy group, an unsubstituted phenylbutoxy group, an unsubstituted phenylpentyloxy group, and an unsubstituted phenylhexyloxy group.
- An unsubstituted benzyloxy group and an unsubstituted phenylbutoxy group are preferred.
- Specific examples of the (C1-C5) alkyl group optionally substituted with a (C3-C6) cyclic alkyl group or a tertiary amino group in R6 and R7 include, for example, a cyclopropyl group, a cyclopentyl group, a cyclohexyl group, methyl Group, ethyl group, isopropyl group, n-butyl group, 3-dimethylaminopropyl group, 5-dimethylaminopentyl group and the like.
- ethyl group, isopropyl group, cyclohexyl group and 3-dimethylaminopropyl group are preferable.
- an isopropyl group is preferable.
- n is preferably in the same range as the general formula (2), and m is 2 to 100, preferably 10 to 100, particularly preferably 15 to 60.
- the sum of a and b is not less than 1 and not greater than m.
- m means the number of polymerized amino acid structural units in the polyamino acid structural portion.
- R5 in the general formula (1) is a hydroxyl group, an aryl (C1-C8) alkoxy group optionally having substituent (s) or —N (R6) —CO—NHR7;
- a structural unit having a cyclic imide structure is included.
- the ratio of R5 in the general formula (1) being a hydroxyl group is 0 to 5%, preferably 0 to 3% of m.
- the proportion of aryl (C1 to C8) alkoxy groups which may have a substituent is 10 to 80%, preferably 20 to 80% of m.
- the proportion of —N (R6) —CO—NHR7 is 11 to 30% of m.
- the ratio of R5 of the compound represented by the general formula (1) being a hydroxyl group is particularly preferably 0% of m.
- the proportion of hydroxyl group is 0% of m means that all the carboxyl groups of the polyamino acid structure portion of the compound represented by the general formula (2) may have a substituent (C1-C8) alkoxy group and / or Or it means substituted with —N (R6) —CO—NHR7.
- the ratio of the hydroxyl group of m can be analyzed by a high performance liquid chromatograph using an anion exchange column, and indicates that m is 0% when not retained on the column. Further, in the present invention, the ratio of the hydroxyl group of m is analyzed by a potentiometric titration method with a base, and when m is 0%, it is indicated by 0.1 mmol / g or less.
- each amino acid structural unit part is bonded in a block form even though they are bonded randomly. May be.
- the aryl (C1 to C8) alkyl alcohol optionally having a substituent used in the present invention is an alcohol corresponding to the aryl (C1 to C8) alkoxy group optionally having the above substituent. is there.
- aryl (C1-C8) alkyl alcohol which may have a substituent
- a commercially available compound may be used.
- a compound prepared by a known organic synthesis method or a compound prepared by applying a known organic reaction can also be used.
- This reaction is carried out in a solvent.
- the solvent used include polar solvents such as dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile, tetrahydrofuran and dioxane, and non-solvents such as benzene, n-hexane and diethyl ether.
- polar solvent such as dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile, tetrahydrofuran and dioxane, and non-solvents such as benzene, n-hexane and diethyl ether.
- a polar solvent is mentioned, Furthermore, water or those mixed solvents etc. are not specifically limited.
- the solvent is usually used in an amount of about 1 to 100 times the weight of the raw material compound.
- Examples of the carbodiimide compound used in this reaction include a carbodiimide compound having a (C3 to C6) cyclic alkyl group or a (C1 to C5) alkyl group optionally substituted with a tertiary amino group.
- a carbodiimide compound having a (C3 to C6) cyclic alkyl group or a (C1 to C5) alkyl group optionally substituted with a tertiary amino group Specifically, for example, diethylcarbodiimide, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (EDC), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC ⁇ HCl), dicyclohexyl Examples thereof include carbodiimide (DCC) and diisopropylcarbodiimide (DIPCI). Among these, DCC or DIPCI is preferable, and DIPCI
- the amount of the carbodiimide compound used in this reaction is 2 (x + y) equivalents or more, more preferably 2 (x + y) equivalents relative to the amount of carboxyl groups (sum of x and y) in the general formula (2). ⁇ 5 (x + y) equivalents.
- the carbodiimide compound may be added to the reaction system from the beginning of the reaction or may be divided and added as appropriate during the reaction.
- a carbodiimide compound of 2 (x + y) equivalent or more was used, and an aryl (C1-C8) alkyl alcohol which may have a substituent, a urea transition product, and a cyclization reaction were performed.
- a carbodiimide compound of 0.5 (x + y) equivalent or more is added so that all the carboxyl groups of the polyamino acid structure portion of the compound represented by the general formula (1) react to introduce a urea transfer product. Complete the reaction and cyclization reaction.
- N-hydroxysuccinimide 1-hydroxybenzotriazole (HOBt)
- N-hydroxy-5-norbornene-2,3-dicarboxylic acid Reaction aids such as imide (HOBN), 4-dimethylaminopyridine (DMAP), N, N-diisopropylethylamine, triethylamine may coexist, with DMAP being preferred.
- the amount used is about 0.1 (x + y) to 5 (x + y) equivalent to the amount of carboxyl group (sum of x and y) in the general formula (2), preferably About 0.2 (x + y) to 2 (x + y) equivalent.
- the amount of the aryl (C1 to C8) alkyl alcohol used in this reaction is 0.4 to 1.0 molar equivalent relative to 1 mol of the carboxyl group of the compound represented by the general formula (2).
- the amount of aryl (C1 to C8) alkyl alcohol introduced is adjusted by adjusting the amount of aryl (C1 to C8) alkyl alcohol used according to the average number of polymerizations of the compound represented by formula (2). it can.
- the reaction temperature is usually 15 to 30 ° C., preferably 20 to 30 ° C., particularly preferably 22 to 27 ° C.
- the reaction time is 2 to 48 hours, preferably 6 to 36 hours.
- the calculation of the reaction rate of 4-phenyl-1-butanol (PhBuOH) in the examples is as follows. ⁇ Calculation of reaction rate of 4-phenyl-1-butanol> Q1 is the total mass of the reaction solution before DIPCI charging. Let Q2 be the mass of the entire reaction solution after DIPCI preparation, The peak area value obtained by the following reversed phase HPLC obtained with the sample solution (sampling amount P1) before DIPCI was charged was AS, The peak area value obtained by the following reversed phase HPLC obtained with the sample solution after DIPCI charging (sampling amount P2) is AT, , (Both sample solutions used the same volumetric flask) are represented by the following formula.
- the anion exchange HPLC measurement conditions in the examples are as follows. In addition, when the reaction product has a carboxyl group in anion exchange HPLC, the reaction product is retained on the column.
- the mixture was washed with DMF (60 mL) and reacted at 25 ° C. for 22 hours.
- the reaction rate of the ester bond of 4-phenyl-1-butanol was constant 20 hours after the start of the reaction.
- anion exchange HPLC the reaction product was retained on the column.
- the adhering part at the time of preparation was washed with DMF (75 mL) and stirred for 3 hours.
- the cation exchange resin Dowex 50w8 was filtered off while washing with ethyl acetate, and the resulting reaction solution was added dropwise to a mixture of heptane and ethyl acetate and stirred. The mixture was allowed to stand overnight, and the resulting precipitate was collected by filtration and dried under reduced pressure to obtain 73.5 g of block copolymer 1.
- Block copolymer 1 (17.60 mg) was dissolved in 1 mL of acetonitrile, and 1 mL of water and 2 mL of 0.5N aqueous sodium hydroxide solution were added. After stirring for 60 minutes at room temperature to hydrolyze the ester bond, the solution was neutralized with 1 mL of 4% phosphoric acid aqueous solution, and the liquid volume was adjusted to 25 mL with 50% aqueous acetonitrile. The prepared solution was quantified for 4-phenyl-1-butanol released by reverse phase HPLC. As a result of analysis, ester-linked 4-phenyl-1-butanol was 16.3% (w / w) of PEG-pAsp-Ac-1.
- reaction rate of ester bond of 4-phenyl-1-butanol was 82.4%, and the introduction rate of 4-phenyl-1-butanol was 55.2% of the carboxyl groups of PEG-pAsp-Ac-1. is there.
- Block copolymer 1 (501.4 mg) was accurately weighed, added with 25 mL of ethanol and suspended, and then dissolved with 35 mL of water. This block copolymer 1 solution was titrated with a 0.1 mol / L potassium hydroxide solution (potentiometric titration method), and the number of carboxyl groups per 1 g of the block copolymer 1 was calculated by the following formula. As a result, it was 0.05 mmol / g. As described above, when the carboxyl group is 0%, it is 0.1 mmol / g or less, so that the block copolymer 1 has no residual carboxyl group.
- Block copolymer 1 (25.18 mg) was accurately weighed, and the internal standard solution was added to make exactly 1 mL to obtain a sample solution.
- isopropyl isocyanate was precisely weighed in a container in which 5 mL of the internal standard solution had been placed in advance, and the internal standard solution was added to make exactly 20 mL. 2.5 mL of this solution was accurately weighed and the internal standard solution was added to make exactly 50 mL, which was used as a standard solution.
- the sample solution and 1 ⁇ L of the standard solution are subjected to gas chromatography under the following conditions to determine the ratios Q T and Q S of the isopropyl isocyanate peak area to the peak area of the internal standard substance, respectively.
- the amount of diisopropyl urea (% (w / w)) in 1 was calculated. As a result, it was 3.5% (w / w).
- the adhering part at the time of preparation was washed with DMF (27 mL) and added, and further reacted at 25 ° C. for 22 hours.
- the reaction rate of the ester bond of 4-phenyl-1-butanol was constant 18 hours after the start of the reaction.
- the reaction product was retained in the column.
- the block copolymer 2 was hydrolyzed in the same manner as in Example 1 and measured by reverse-phase HPLC. As a result, ester-linked 4-phenyl-1-butanol was found to be 15.5% of PEG-pAsp-Ac-2. (W / w). The reaction rate of ester bond of 4-phenyl-1-butanol is 77.3%, and the introduction rate of 4-phenyl-1-butanol is 56.4% of the carboxyl group of PEG-pAsp-Ac-2. .
- the block copolymer 3 was hydrolyzed in the same manner as in Example 1 and measured by reverse phase HPLC.
- ester-linked 4-phenyl-1-butanol was 17.2% of PEG-pAsp-Ac-3. (W / w).
- the reaction rate of ester bond of 4-phenyl-1-butanol is 86.8%, and the introduction rate of 4-phenyl-1-butanol is 53.0% of the carboxy group of PEG-pAsp-Ac-3. .
- the block copolymer 3 was titrated with a 0.1 mol / L potassium hydroxide solution in the same manner as in Example 1 (potentiometric titration method), the number of carboxyl groups per gram was 0.05 mmol / g. As described above, when the carboxyl group is 0%, it is 0.1 mmol / g or less, so that the block copolymer 3 has no residual carboxyl group.
- the block copolymer 4 was hydrolyzed in the same manner as in Example 1 and measured by reverse phase HPLC.
- ester-linked 4-phenyl-1-butanol was found to be 16.6% of PEG-pAsp-Ac-4 ( w / w). Therefore, the reaction rate of the ester bond of 4-phenyl-1-butanol used was 81.4%, and the introduction rate of 4-phenyl-1-butanol was 54.5% of the carboxyl groups of PEG-pAsp-Ac-4. %.
- the block copolymer was hydrolyzed in the same manner as in Example 1 and measured by reverse phase HPLC. As a result, ester-linked 4-phenyl-1-butanol was found to be 15.5% (w / W). The reaction rate of ester bond of 4-phenyl-1-butanol is 49.0%, and the introduction rate of 4-phenyl-1-butanol is 49.0% of the carboxy group of PEG-pAsp-Ac-5. .
- the block copolymer 5 was measured by anion exchange HPLC under the same conditions as in Example 1, and a peak was detected at a retention time of 14.3 minutes.
- ester-linked 4-phenyl-1-butanol was found to be 17.0% (w / w) of the above general formula (2). )Met.
- the reaction rate of ester bond of 4-phenyl-1-butanol is 77.0%, and the introduction rate of 4-phenyl-1-butanol is 53.9% of the carboxy group of PEG-pAsp-Ac-6. .
- the crude crystals were measured by anion exchange HPLC under the same conditions as in Example 1, and a peak was detected at a retention time of 16.9 minutes.
- the block copolymer 6 was hydrolyzed in the same manner as in Example 1 and measured by reverse phase HPLC. As a result, ester-bonded 4-phenyl-1-butanol was found to be 15.8% of the above general formula (2) ( w / w). The introduction rate of 4-phenyl-1-butanol was 50% after the second stage reaction.
- the block copolymer 6 was titrated with a 0.1 mol / L potassium hydroxide solution in the same manner as in Example 1 (potentiometric titration method), the number of carboxyl groups per gram was 0.04 mol / g. As described above, when the carboxyl group is 0%, it is 0.1 mmol / g or less, so that the block copolymer 6 has no residual carboxyl group.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Polyamides (AREA)
- Polyethers (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
1)下記一般式(2)
で表される化合物と、置換基を有していてもよいアリール(C1~C8)アルキルアルコールと、一般式(2)中のカルボキシル基の量(xとyの和)に対して2(x+y)当量以上のカルボジイミド系化合物と溶媒中15~30℃で2~48時間反応させることを特徴とする、下記一般式(1)
で表されるブロック共重合体の製造方法である。
<4-フェニル-1-ブタノールの反応率の算出>
DIPCI仕込前の反応液全体の質量をQ1、
DIPCI仕込後の反応液全体の質量をQ2、とし、
DIPCI仕込前の試料溶液(サンプリング量P1)で得られる下記の逆相HPLCにて求めたピーク面積値をAS、
DIPCI仕込後の試料溶液(サンプリング量P2)で得られる下記の逆相HPLCにて求めたピーク面積値をAT、
とするとき、(両試料溶液とも同じメスフラスコを使用した)以下の式で表される。
<陰イオン交換HPLC測定条件>
カラム:TSKgel DEAE-5PW(東ソー株式会社製)
サンプル濃度:5mg/mL
注入量:20μL
カラム温度:40℃
移動相
(A)20mMトリス塩酸緩衝液(pH8.0):アセトニトリル=80:20
(B)20mMトリス塩酸緩衝液+1M塩化ナトリウム水溶液(pH8.0):アセトニトリル=80:20
流速:1mL/min
グラジエント条件 B%(分):10(0)、10(5)、100(40)、
10(40.1)、stop(50.1)
検出器:紫外可視分光光度計検出器(検出波長260nm)
<逆相HPLC測定条件>
[HPLC]-絶対検量線法-
カラム:Inertsil ODS-3 5μm(4.6 mmI.D.×150 mmL)
注入量:20 μL
カラム温度:40℃
移動相:0.1%H3PO4/(H2O:CH3CN=60:40)
流速:1.0 mL/min.
検出器:紫外可視分光光度計検出器(検出波長260nm)
ブロック共重合体1の製造
特許文献2に記載された方法にて製造したPEG(平均分子量12000)-pAsp(ポリアスパラギン酸;平均重合数41.6)-Ac(前記一般式(2)のR1がメチル基、R2がトリメチレン基、R3がメチレン基、R4がアセチル基、nが約272、xが約10.4、yが約31.2、以下PEG-pAsp-Ac-1と略す)65.0gにDMF(1132mL)を加え、35℃で溶解し、DMAP(19.2g)及び4-フェニル-1-ブタノール(15.9g:0.106モル:PEG-pAsp-Ac-1のカルボシキル基1モルに対し、0.67モル当量)を加え、仕込み時の付着分をDMF(66mL)で洗いこんだ。溶解確認後、反応液を25℃とし、DIPCI(39.7g:PEG-pAsp-Ac-1のカルボシキル基に対して2(x+y)当量=83.2当量)を添加、仕込み時の付着分をDMF(60mL)で洗いこみ、25℃で22時間反応させた。このとき、反応開始20時間後で、4-フェニル-1-ブタノールのエステル結合の反応率は一定になっていた。一方、陰イオン交換HPLCによる分析で、反応物はカラムに保持されていた。反応22時間後にDIPCI(9.92g:PEG-pAsp-Ac-1のカルボシキル基に対して0.5(x+y)当量=20.8当量)を添加し反応を継続させた。反応物が陰イオン交換HPLCによる分析においてカラムに保持されなくなることを確認し、反応開始26時間後に反応を終了させた。反応液をヘプタンと酢酸エチルの混液に滴下し、撹拌した。一晩静置し、得られた沈殿をろ過回収して減圧乾燥し、粗結晶76.2gを得た。
この粗結晶(75.0g)をDMF(1050mL)に溶解後、陽イオン交換樹脂ダウエックス50w8(248mL)を加えた。さらに仕込み時の付着分をDMF(75mL)で洗いこんで加え、3時間撹拌した。陽イオン交換樹脂ダウエックス50w8を酢酸エチルで洗いながらろ去後、得られた反応液をヘプタンと酢酸エチルの混液に滴下し、撹拌した。一晩静置し、得られた沈殿をろ過回収して減圧乾燥し、ブロック共重合体1を73.5g得た。
試験条件
検出器:水素炎イオン化検出器
カラム:内径0.53mm、長さ30mのフューズドシリカ管の内面にガスクロマトグラフィー用ポリエチレングリコールを厚さ1.0μmで被覆
カラム温度:50℃を8分間、その後、毎分25℃で200℃まで昇温
注入口温度:270℃付近の一定温度
検出器温度:250℃付近の一定温度
キャリヤーガス:ヘリウム
流量:3.5mL/min
スプリット比: 1:50
面積測定範囲:10分
ブロック共重合体2の製造
特許文献2に記載された方法にて製造したPEG(平均分子量12000)-pAsp(ポリアスパラギン酸;平均重合数36.4)-Ac(前記一般式(2)のR1がメチル基、R2がトリメチレン基、R3がメチレン基、R4がアセチル基、nが約272、xが約9.1、yが約27.3、以下PEG-pAsp-Ac-2と略す)30.0gにDMF(536mL)を加え、35℃で溶解し、DMAP(8.18g)及び4-フェニル-1-ブタノール(7.35g:0.049モル:PEG-pAsp-Ac-2のカルボシキル基1モルに対し、0.73モル当量)を加え、仕込み時の付着分をDMF(27mL)で洗いこんだ。溶解確認後、反応液を25℃とし、DIPCI(16.9g:PEG-pAsp-Ac-2のカルボシキル基に対して2(x+y)当量=72.8当量)を添加した。仕込み時の付着分をDMF(27mL)で洗いこんで加え、さらに25℃で22時間反応させた。このとき、反応開始18時間後で、4-フェニル-1-ブタノールのエステル結合の反応率は一定になっていた。一方、陰イオン交換カラムを用いた高速液体クロマトグラフによる分析で、反応物はカラムに保持されていた。反応22時間後にDIPCI(4.23g:PEG-pAsp-Ac-2のカルボシキル基に対して0.5(x+y)当量=18.2当量)を添加し反応を継続させ、反応物が陰イオン交換HPLCによる分析においてカラムに保持されなくなることを確認し、反応開始後26時間後に反応を終了させた。反応液をヘプタンと酢酸エチルの混液に滴下し、撹拌した。一晩静置し、得られた沈殿をろ過回収して減圧乾燥し、粗結晶34.3gを得た。
この粗結晶(33.5g)をDMF(469mL)に溶解後、陽イオン交換樹脂ダウエックス50w8(111mL)を加え、仕込み時の付着分をDMF(34mL)で洗いこみ、3時間撹拌した。陽イオン交換樹脂ダウエックス50w8を酢酸エチルで洗いながらろ去後、得られた反応液をヘプタンと酢酸エチルの混液に滴下し、撹拌した。一晩静置し、得られた沈殿をろ過回収して減圧乾燥し、ブロック共重合体2を32.2g得た。
ブロック共重合体3の製造
特許文献2に記載された方法にて製造したPEG(平均分子量12000)-pAsp(ポリアスパラギン酸;平均重合数46.8)-Ac(前記一般式(1)のR1がメチル基、R2がトリメチレン基、R3がメチレン基、R4がアセチル基、nが約272、xが約11.7、yが約35.1、以下PEG-pAsp-Ac-3と略す)30.0gにDMF(570mL)を加え、35℃で溶解し、DMAP(9.68g)及び4-フェニル-1-ブタノール(7.29g:0.0486モル:(PEG-pAsp-Ac-3のカルボシキル基1モルに対し、0.61モル当量)を加え、仕込み時の付着分をDMF(32mL)で洗いこんだ。溶解確認後、反応液を25℃とし、DIPCI(20.00g:PEG-pAsp-Ac-3のカルボシキル基に対して2(x+y)当量=93.6当量)を添加、仕込み時の付着分をDMF(32mL)で洗いこみ、同温度で22時間反応させた。このとき、反応開始18時間後で、4-フェニル-1-ブタノールの反応率は一定になっていた。一方、陰イオン交換HPLCによる分析で、反応物は、カラムに保持されていた。反応開始22時間後にDIPCI(5.0g:PEG-pAsp-Acのカルボシキル基に対して0.5(x+y)当量=23.4当量)を添加し反応を継続させた。反応物が陰イオン交換カラムを用いた高速液体クロマトグラフによる分析においてカラムに保持されなくなることを確認し、反応開始29時間後に反応を終了した。反応液をヘプタンと酢酸エチルの混液に滴下し、撹拌した。一晩静置し、得られた沈殿をろ過回収して減圧乾燥し、粗結晶35.4gを得た。
この粗結晶(34.5g)をDMF(483mL)に溶解後、陽イオン交換樹脂ダウエックス50w8(114mL)を加え、仕込み時の付着分をDMF(35mL)で洗いこんだ。その後3時間撹拌したのち陽イオン交換樹脂ダウエックス50w8を酢酸エチルで洗いながらろ去後、得られた反応液をヘプタンと酢酸エチルの混液に滴下し、撹拌した。一晩静置し、得られた沈殿をろ過回収して減圧乾燥し、ブロック共重合体3を33.1g得た。
ブロック共重合体4の製造
特許文献2に記載された方法にて製造したPEG(平均分子量12000)-pAsp(ポリアスパラギン酸;平均重合数41.6)-Ac(前記一般式(1)のR1がメチル基、R2がトリメチレン基、R3がメチレン基、R4がアセチル基、nが約272、xが約10.4、yが約31.2、以下PEG-pAsp-Ac-4と略す)62.0gにDMF(1102mL)を加え、35℃で溶解し、DMAP(18.69g)及び4-フェニル-1-ブタノール(15.50g:0.103モル:PEG-pAsp-Ac-4のカルボシキル基1モルに対し、0.67モル当量)を加え、仕込み時の付着分をDMF(61mL)で洗いこんだ。溶解確認後、反応液を25℃とし、DIPCI(38.62g:PEG-pAsp-Ac-4のカルボシキル基に対して2(x+y)当量=83.2当量)を添加、仕込み時の付着分をDMF(61mL)で洗いこみ、25℃で22時間反応させた。このとき、反応開始20時間後で、4-フェニル-1-ブタノールの反応率は一定になっていた。一方、陰イオン交換カラムを用いた高速液体クロマトグラフによる分析で、反応物は、カラムに保持されていた。反応22時間後にDIPCI(9.66g:PEG-pAsp-Acのカルボシキル基に対して0.5(x+y)当量=20.8当量)を添加し反応を継続させ、反応物が陰イオン交換HPLCによる分析においてカラムに保持されなくなることを確認し、反応開始25時間後に反応を終了し、反応液をヘプタンと酢酸エチルの混液に滴下し、撹拌した。一晩静置し、得られた沈殿をろ過回収して減圧乾燥し、粗結晶72.9gを得た。
この粗結晶(71.5g)をDMF(1001mL)に溶解後、陽イオン交換樹脂ダウエックス50w8(236mL)を加え、仕込み時の付着分をDMF(72mL)で洗いこみ、3時間撹拌した。陽イオン交換樹脂ダウエックス50w8を酢酸エチルで洗いながらろ去後、得られた反応液をヘプタンと酢酸エチルの混液に滴下し、撹拌した。一晩静置し、得られた沈殿をろ過回収して減圧乾燥し、ブロック共重合体4を69.7g得た。
ブロック共重合体5の製造
特許文献2に記載された方法にて製造したPEG(平均分子量12000)-pAsp(ポリアスパラギン酸;平均重合数43.2)-Ac(上記一般式(2)のR1がメチル基、R2がトリメチレン基、R3がメチレン基、R4がアセチル基、nが約272、xが約10.8、yが約32.4、以下PEG-pAsp-Ac-5と略す)3.50gにDMF(70mL)を加え、35℃で溶解し、DMAP(0.87g)及び4-フェニル-1-ブタノール(1.34g:0.0089モル:PEG-pAsp-Ac-5のカルボシキル基1モルに対して1.00モル当量)、DIPCI(1.12g:PEG-pAsp-Ac-5のカルボシキル基1モルに対して1当量)を添加し、35℃で26時間反応させた。この反応液をジイソプロピルエーテルとエタノールの混液に滴下し、沈殿をろ過回収して減圧乾燥し、粗結晶3.70gを得た。この粗結晶を50%アセトニトリル水溶液に溶解後、陽イオン交換樹脂ダウエックス50w8(40mL)に通液し、更に、50%アセトニトリルで洗浄した。溶出液を減圧濃縮後、凍結乾燥してブロック共重合体5を3.72g得た。
ブロック共重合体6の製造
特許文献2に記載された方法にて製造したPEG(平均分子量12000)-pAsp(ポリアスパラギン酸;平均重合数41.0)-Ac(前記一般式(2)のR1がメチル基、R2がトリメチレン基、R3がメチレン基、R4がアセチル基、nが約272、xが約10.3、yが約30.8、以下PEG-pAsp-Ac-6と略す)1.73kgにDMF(13.0L)を加え、35℃で溶解し、DMAP(412g、DMFによる洗いこみ8.7L)及び4-フェニル-1-ブタノール(443g:2.95モル:PEG-pAsp-Ac-6のカルボシキル基1モルに対して0.70モル当量、DMFによる洗いこみ2.2L)を加え、反応液を22.5℃に冷却した。DIPCI(532g:PEG-pAsp-Ac-6のカルボシキル基1モルに対して1当量、DMFによる洗いこみ2.2L)を添加し、22.5℃で22時間反応させた。反応液に酢酸エチルとヘプタンを加えて撹拌し、得られた沈殿をろ過回収して減圧乾燥し、粗結晶2.08kgを得た。
Claims (4)
- 下記一般式(2)
で表される化合物と、置換基を有していてもよいアリール(C1~C8)アルキルアルコールと、一般式(2)中のカルボキシル基の量(xとyの和)に対して2(x+y)当量以上のカルボジイミド系化合物と溶媒中15~30℃で2~48時間反応させることを特徴とする下記一般式(1)
で表されるブロック共重合体の製造方法。 - R1がメチル基、R2がトリメチレン基、R3がメチレン基、R4がアセチル基であり、nが80~400、mは15~60、aは5~60、bは5~60である請求項1に記載のブロック共重合体の製造方法。
- カルボジイミド系化合物が、ジエチルカルボジイミド、ジイソプロピルカルボジイミド、ジシクロヘキシルカルボジイミド、又は、1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド若しくはその無機酸塩である請求項1又は2に記載のブロック共重合体の製造方法。
- カルボジイミド系化合物がジイソプロピルカルボジイミドである請求項1~3のいずれか1項に記載のブロック共重合体の製造方法。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201280043928.7A CN103874722B (zh) | 2011-09-11 | 2012-08-31 | 嵌段共聚物的制造方法 |
US14/241,924 US9346923B2 (en) | 2011-09-11 | 2012-08-31 | Method for manufacturing block copolymer |
ES12830758.4T ES2635117T3 (es) | 2011-09-11 | 2012-08-31 | Método para la fabricación de un copolímero de bloques |
JP2013532568A JP5711378B2 (ja) | 2011-09-11 | 2012-08-31 | ブロック共重合体の製造方法 |
RU2014114264A RU2623426C2 (ru) | 2011-09-11 | 2012-08-31 | Способ получения блок-сополимера |
AU2012305405A AU2012305405B2 (en) | 2011-09-11 | 2012-08-31 | Method for manufacturing block copolymer |
CA2847114A CA2847114C (en) | 2011-09-11 | 2012-08-31 | Method for manufacturing block copolymer |
EP12830758.4A EP2754682B1 (en) | 2011-09-11 | 2012-08-31 | Method for manufacturing block copolymer |
BR112014005452-5A BR112014005452B1 (pt) | 2011-09-11 | 2012-08-31 | método de produção de copolímero de bloco |
KR1020147006350A KR101849142B1 (ko) | 2011-09-11 | 2012-08-31 | 블록 공중합체의 제조방법 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011-197760 | 2011-09-11 | ||
JP2011197760 | 2011-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013035641A1 true WO2013035641A1 (ja) | 2013-03-14 |
Family
ID=47832088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/072160 WO2013035641A1 (ja) | 2011-09-11 | 2012-08-31 | ブロック共重合体の製造方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US9346923B2 (ja) |
EP (1) | EP2754682B1 (ja) |
JP (1) | JP5711378B2 (ja) |
KR (1) | KR101849142B1 (ja) |
CN (1) | CN103874722B (ja) |
AU (1) | AU2012305405B2 (ja) |
BR (1) | BR112014005452B1 (ja) |
CA (1) | CA2847114C (ja) |
ES (1) | ES2635117T3 (ja) |
PT (1) | PT2754682T (ja) |
RU (1) | RU2623426C2 (ja) |
TW (1) | TWI544012B (ja) |
WO (1) | WO2013035641A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1792927T3 (pl) * | 2004-09-22 | 2013-09-30 | Nippon Kayaku Kk | Nowy kopolimer blokowy, preparat micelarny i lek przeciwnowotworowy zawierający ten preparat micelarny jako składnik czynny |
USRE46190E1 (en) | 2007-09-28 | 2016-11-01 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
CN101977631A (zh) * | 2008-03-18 | 2011-02-16 | 日本化药株式会社 | 生理活性物质的高分子量偶联物 |
JP5366940B2 (ja) | 2008-05-08 | 2013-12-11 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
CN103221054A (zh) | 2010-11-17 | 2013-07-24 | 日本化药株式会社 | 新的胞苷类代谢拮抗剂的高分子衍生物 |
US10876152B2 (en) | 2012-09-04 | 2020-12-29 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
US11913065B2 (en) * | 2012-09-04 | 2024-02-27 | Guardent Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
CA2990369A1 (en) | 2015-06-24 | 2016-12-29 | Nippon Kayaku Kabushiki Kaisha | Novel platinum (iv) complex |
RU2715048C2 (ru) * | 2015-09-14 | 2020-02-25 | Ниппон Каяку Кабусики Каися | Полимерный конъюгат гексакоординированного комплекса платины |
CA3009130A1 (en) * | 2015-12-22 | 2017-06-29 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of sulfoxide derivative-coordinated platinum(ii) complex |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06107565A (ja) | 1992-08-14 | 1994-04-19 | Res Dev Corp Of Japan | 物理吸着型高分子ミセル医薬 |
JPH06206815A (ja) | 1992-10-26 | 1994-07-26 | Nippon Kayaku Co Ltd | ブロック共重合体−抗癌剤複合体医薬製剤 |
JPH11335267A (ja) | 1998-05-27 | 1999-12-07 | Nano Career Kk | 水難溶性薬物を含有するポリマーミセル系 |
JP2001226294A (ja) | 2000-02-09 | 2001-08-21 | Nano Career Kk | 薬物が封入されたポリマーミセルの製造方法および該ポリマーミセル組成物 |
WO2004082718A1 (ja) | 2003-03-20 | 2004-09-30 | Nippon Kayaku Kabushiki Kaisha | 難水溶性抗癌剤と新規ブロック共重合体を含むミセル調製物 |
WO2006033296A1 (ja) | 2004-09-22 | 2006-03-30 | Nippon Kayaku Kabushiki Kaisha | 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤 |
JP2007191643A (ja) * | 2006-01-20 | 2007-08-02 | Mitsui Chemicals Inc | 生体への定着性が付与されたポリアミノ酸誘導体 |
WO2007111211A1 (ja) * | 2006-03-28 | 2007-10-04 | Nippon Kayaku Kabushiki Kaisha | タキサン類の高分子結合体 |
WO2009041570A1 (ja) * | 2007-09-28 | 2009-04-02 | Nippon Kayaku Kabushiki Kaisha | ステロイド類の高分子結合体 |
WO2009142326A1 (ja) * | 2008-05-23 | 2009-11-26 | ナノキャリア株式会社 | ドセタキセル高分子誘導体、並びにその製造方法及びその用途 |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1467587A (en) | 1974-07-11 | 1977-03-16 | Nestle Sa | Preparation of an asparagine or a glutamine |
GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
JPS6296088A (ja) | 1985-10-22 | 1987-05-02 | Kanebo Ltd | 抗腫瘍性物質の製法 |
US4734512A (en) | 1985-12-05 | 1988-03-29 | Bristol-Myers Company | Intermediates for the production of podophyllotoxin and related compounds and processes for the preparation and use thereof |
CH667874A5 (fr) | 1985-12-19 | 1988-11-15 | Battelle Memorial Institute | Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments. |
JPS6310789A (ja) | 1986-07-01 | 1988-01-18 | Nippon Kayaku Co Ltd | 新規ポドフイロトキシン誘導体 |
JPS6323884A (ja) | 1986-07-17 | 1988-02-01 | Nippon Kayaku Co Ltd | 新規ポドフイロトキシン誘導体 |
JPS6461423A (en) | 1987-09-02 | 1989-03-08 | Nippon Kayaku Kk | Water-soluble polymeric carcinostatic agent |
JPS6461422A (en) | 1987-09-02 | 1989-03-08 | Nippon Kayaku Kk | Water-soluble polymeric carcinostatic agent |
US5182203A (en) | 1989-03-29 | 1993-01-26 | E. I. Du Pont De Nemours And Company | Bifunctional compounds useful in catalyzed reporter deposition |
JP2517760B2 (ja) | 1989-05-11 | 1996-07-24 | 新技術事業団 | 水溶性高分子化医薬製剤 |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
JP3310000B2 (ja) | 1990-11-07 | 2002-07-29 | 靖久 桜井 | 水溶性高分子抗癌剤及び薬物担持用担体 |
JPH05117385A (ja) | 1991-10-31 | 1993-05-14 | Res Dev Corp Of Japan | ブロツク共重合体の製造法、ブロツク共重合体及び水溶性高分子抗癌剤 |
WO1993024476A1 (en) | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
US5614549A (en) | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
JPH06206830A (ja) | 1992-10-27 | 1994-07-26 | Nippon Kayaku Co Ltd | ブロック共重合体−薬剤複合体及び高分子ブロック共重合体 |
JP3268913B2 (ja) | 1992-10-27 | 2002-03-25 | 日本化薬株式会社 | 高分子担体 |
FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
US5985548A (en) | 1993-02-04 | 1999-11-16 | E. I. Du Pont De Nemours And Company | Amplification of assay reporters by nucleic acid replication |
DE4307114A1 (de) | 1993-03-06 | 1994-09-08 | Basf Ag | Verfahren zur Herstellung von Umsetzungsprodukten aus Polyasparaginsäureamid und Aminosäuren und ihre Verwendung |
JP2894923B2 (ja) | 1993-05-27 | 1999-05-24 | 日立造船株式会社 | ウォータージェット式双胴船のジェット水吸込口部構造 |
US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
JPH0848766A (ja) | 1994-05-30 | 1996-02-20 | Mitsui Toatsu Chem Inc | 重合体及びその製造方法 |
US5571889A (en) | 1994-05-30 | 1996-11-05 | Mitsui Toatsu Chemicals, Inc. | Polymer containing monomer units of chemically modified polyaspartic acids or their salts and process for preparing the same |
US5552517A (en) | 1995-03-03 | 1996-09-03 | Monsanto Company | Production of polysuccinimide in an organic medium |
SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
JP2694923B2 (ja) | 1995-08-21 | 1997-12-24 | 科学技術振興事業団 | 水溶性高分子化医薬製剤 |
WO1997033552A1 (en) | 1996-03-12 | 1997-09-18 | Pg-Txl Company, L.P. | Water soluble paclitaxel prodrugs |
JP4420472B2 (ja) | 1996-04-15 | 2010-02-24 | 旭化成株式会社 | 薬物複合体 |
US5877205A (en) | 1996-06-28 | 1999-03-02 | Board Of Regents, The University Of Texas System | Parenteral paclitaxel in a stable non-toxic formulation |
WO1998002426A1 (fr) | 1996-07-15 | 1998-01-22 | Kabushiki Kaisha Yakult Honsha | Derives de taxane et medicaments les contenant |
DE69725877T2 (de) | 1996-08-26 | 2004-07-22 | Transgene S.A. | Kationische lipid-nukleinsäure komplexe |
GB9625895D0 (en) | 1996-12-13 | 1997-01-29 | Riley Patrick A | Novel compound useful as therapeutic agents and assay reagents |
EP0879604B1 (de) | 1997-05-09 | 2003-04-09 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Konjugat, umfassend einen Folsäureantagonisten und einen Träger |
EP1037649B1 (en) | 1997-12-17 | 2009-09-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6824766B2 (en) | 1998-04-17 | 2004-11-30 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
IN191203B (ja) | 1999-02-17 | 2003-10-04 | Amarnath Prof Maitra | |
US6207832B1 (en) | 1999-04-09 | 2001-03-27 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
US20010041189A1 (en) | 1999-04-13 | 2001-11-15 | Jingya Xu | Poly(dipeptide) as a drug carrier |
US6380405B1 (en) | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
ES2240163T3 (es) | 1999-09-14 | 2005-10-16 | Tepha, Inc. | Utilizaciones terapeuticas de polimeros y de oligomeros a base de gamma-hidroxibutirano (ghb). |
US6376470B1 (en) | 1999-09-23 | 2002-04-23 | Enzon, Inc. | Polymer conjugates of ara-C and ara-C derivatives |
BRPI0014652B1 (pt) | 1999-10-12 | 2016-08-09 | Cell Therapeutics Inc | fabricação de conjugados de agente terapêutico-poliglutamato |
US20030054977A1 (en) | 1999-10-12 | 2003-03-20 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
WO2001064198A2 (en) | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
US20020016285A1 (en) | 2000-03-17 | 2002-02-07 | Rama Bhatt | Polyglutamic acid-camptothecin conjugates and methods of preparation |
US20020161062A1 (en) | 2001-11-06 | 2002-10-31 | Biermann Paul J. | Structure including a plurality of cells of cured resinous material, method of forming the structure and apparatus for forming the structure |
AU7522601A (en) | 2000-06-02 | 2001-12-11 | Eidgenoess Tech Hochschule | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
JP2002069184A (ja) | 2000-06-12 | 2002-03-08 | Mitsui Chemicals Inc | 重合体及びその製造方法 |
AU2001296215A1 (en) | 2000-07-17 | 2002-01-30 | Oxi-Gene, Inc. | Efficient method of synthesizing combretastatin a-4 prodrugs |
US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
WO2002065986A2 (en) | 2001-02-16 | 2002-08-29 | Cellgate, Inc. | Transporters comprising spaced arginine moieties |
EP1361895B1 (en) | 2001-02-20 | 2007-11-14 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
AU2002251988A1 (en) | 2001-02-20 | 2002-09-04 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
PL222061B1 (pl) | 2001-06-20 | 2016-06-30 | Nippon Kayaku Kk | Sposób produkcji kopolimeru blokowego, nośnik polimerowy oraz polimerowy preparat farmaceutyczny |
WO2003035008A2 (en) | 2001-10-26 | 2003-05-01 | Oxigene, Inc. | Functionalized stilbene derivatives as improved vascular targeting agents |
EP1456180B1 (en) | 2001-12-21 | 2007-10-03 | Vernalis (Cambridge) Limited | 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use |
CA2476182A1 (en) | 2002-03-01 | 2003-09-12 | The Administrators Of The Tulane Educational Fund | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
CN100475269C (zh) | 2002-03-05 | 2009-04-08 | 北京键凯科技有限公司 | 亲水性聚合物-谷氨酸寡肽与药物分子的结合物、包含该结合物的组合物及用途 |
CN100490817C (zh) | 2002-03-26 | 2009-05-27 | 万有制药株式会社 | 抗肿瘤吲哚并吡咯并咔唑衍生物和其它抗肿瘤药物联合用药 |
US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
JP2003342167A (ja) | 2002-05-24 | 2003-12-03 | Nano Career Kk | カンプトテシン誘導体の製剤およびその調製方法 |
JP2003342168A (ja) | 2002-05-24 | 2003-12-03 | Nano Career Kk | 注射用薬物含有ポリマーミセル製剤の製造方法 |
JP4270485B2 (ja) | 2002-05-28 | 2009-06-03 | 第一三共株式会社 | タキサン類の還元方法 |
JP2004010479A (ja) | 2002-06-03 | 2004-01-15 | Japan Science & Technology Corp | ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法 |
JP4745664B2 (ja) | 2002-10-31 | 2011-08-10 | 日本化薬株式会社 | カンプトテシン類の高分子誘導体 |
GB0228417D0 (en) | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
US7169892B2 (en) | 2003-01-10 | 2007-01-30 | Astellas Pharma Inc. | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems |
JP4921162B2 (ja) | 2003-02-11 | 2012-04-25 | ヴァーナリス(ケンブリッジ)リミテッド | 熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類 |
EP1594482A1 (en) | 2003-03-26 | 2005-11-16 | LTT Bio-Pharma Co., Ltd. | Intravenous nanoparticles for targeting drug delivery and sustained drug release |
GB0309637D0 (en) | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
EP1666064A4 (en) | 2003-08-22 | 2008-12-17 | Kyowa Hakko Kogyo Kk | MEANS FOR THE TREATMENT OF DISEASES RELATED TO IMMUNOGLOBULIN GEN TRANSLATION |
EP1680073B1 (en) | 2003-10-21 | 2013-01-02 | IGF Oncology, LLC | Compounds and method for treating cancer |
FR2862536B1 (fr) | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques |
US7176185B2 (en) | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
EP2497785B1 (en) | 2004-01-07 | 2018-09-12 | Seikagaku Corporation | Hyaluronic acid derivative and drug containing the same |
CN101103144B (zh) | 2004-11-16 | 2013-02-06 | 海珀里昂催化国际有限公司 | 制备负载在碳纳米管网络上的催化剂的方法 |
KR101374553B1 (ko) | 2004-11-18 | 2014-03-17 | 신타 파마슈티칼스 코프. | Hsp90 활성을 조절하는 트리아졸 화합물 |
KR20070112400A (ko) | 2005-03-09 | 2007-11-23 | 니폰 가야꾸 가부시끼가이샤 | 신규의 hsp90 저해제 |
US8399464B2 (en) | 2005-03-09 | 2013-03-19 | Nippon Kayaku Kabushiki Kaisha | HSP90 inhibitor |
WO2006095668A1 (ja) | 2005-03-09 | 2006-09-14 | Toray Industries, Inc. | 微粒子および医薬品組成物 |
JP2008137894A (ja) | 2005-03-22 | 2008-06-19 | Nippon Kayaku Co Ltd | 新規なアセチレン誘導体 |
JPWO2006115293A1 (ja) | 2005-04-22 | 2008-12-18 | 国立大学法人 東京大学 | pH応答性高分子ミセルの調製に用いる新規ブロック共重合体及びその製造法 |
RU2404980C2 (ru) | 2005-05-11 | 2010-11-27 | Ниппон Каяку Кабусики Кайся | Полимерное производное антиметаболита цитидина |
EP1880721A4 (en) | 2005-05-12 | 2009-05-27 | Nipro Corp | MEANS FOR IMPROVING CIRCULAR DISORDER |
US20080280937A1 (en) | 2005-08-19 | 2008-11-13 | Christopher Paul Leamon | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives |
CN1800238A (zh) | 2005-12-05 | 2006-07-12 | 中国科学院长春应用化学研究所 | 有生物功能的脂肪族聚酯—聚氨基酸共聚物及合成方法 |
JP2007182407A (ja) | 2006-01-10 | 2007-07-19 | Medgel Corp | 徐放性ハイドロゲル製剤 |
CA2652656A1 (en) | 2006-05-18 | 2007-11-29 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
WO2008010463A1 (fr) | 2006-07-19 | 2008-01-24 | Nippon Kayaku Kabushiki Kaisha | Conjugué polymère d'une combrétastatine |
JP5548364B2 (ja) | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | レゾルシノール誘導体の高分子結合体 |
JP5503872B2 (ja) | 2006-11-06 | 2014-05-28 | 日本化薬株式会社 | 核酸系代謝拮抗剤の高分子誘導体 |
EP2090607B1 (en) | 2006-11-08 | 2015-05-20 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
CN101977631A (zh) * | 2008-03-18 | 2011-02-16 | 日本化药株式会社 | 生理活性物质的高分子量偶联物 |
JP5366940B2 (ja) | 2008-05-08 | 2013-12-11 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
JP5544357B2 (ja) | 2009-05-15 | 2014-07-09 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
CN103221054A (zh) | 2010-11-17 | 2013-07-24 | 日本化药株式会社 | 新的胞苷类代谢拮抗剂的高分子衍生物 |
-
2012
- 2012-08-31 RU RU2014114264A patent/RU2623426C2/ru active
- 2012-08-31 PT PT128307584T patent/PT2754682T/pt unknown
- 2012-08-31 BR BR112014005452-5A patent/BR112014005452B1/pt not_active IP Right Cessation
- 2012-08-31 CN CN201280043928.7A patent/CN103874722B/zh not_active Expired - Fee Related
- 2012-08-31 US US14/241,924 patent/US9346923B2/en active Active
- 2012-08-31 CA CA2847114A patent/CA2847114C/en not_active Expired - Fee Related
- 2012-08-31 ES ES12830758.4T patent/ES2635117T3/es active Active
- 2012-08-31 KR KR1020147006350A patent/KR101849142B1/ko active IP Right Grant
- 2012-08-31 WO PCT/JP2012/072160 patent/WO2013035641A1/ja active Application Filing
- 2012-08-31 AU AU2012305405A patent/AU2012305405B2/en not_active Ceased
- 2012-08-31 EP EP12830758.4A patent/EP2754682B1/en not_active Not-in-force
- 2012-08-31 JP JP2013532568A patent/JP5711378B2/ja active Active
- 2012-09-11 TW TW101133180A patent/TWI544012B/zh not_active IP Right Cessation
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06107565A (ja) | 1992-08-14 | 1994-04-19 | Res Dev Corp Of Japan | 物理吸着型高分子ミセル医薬 |
JPH06206815A (ja) | 1992-10-26 | 1994-07-26 | Nippon Kayaku Co Ltd | ブロック共重合体−抗癌剤複合体医薬製剤 |
JPH11335267A (ja) | 1998-05-27 | 1999-12-07 | Nano Career Kk | 水難溶性薬物を含有するポリマーミセル系 |
JP2001226294A (ja) | 2000-02-09 | 2001-08-21 | Nano Career Kk | 薬物が封入されたポリマーミセルの製造方法および該ポリマーミセル組成物 |
WO2004082718A1 (ja) | 2003-03-20 | 2004-09-30 | Nippon Kayaku Kabushiki Kaisha | 難水溶性抗癌剤と新規ブロック共重合体を含むミセル調製物 |
WO2006033296A1 (ja) | 2004-09-22 | 2006-03-30 | Nippon Kayaku Kabushiki Kaisha | 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤 |
JP2007191643A (ja) * | 2006-01-20 | 2007-08-02 | Mitsui Chemicals Inc | 生体への定着性が付与されたポリアミノ酸誘導体 |
WO2007111211A1 (ja) * | 2006-03-28 | 2007-10-04 | Nippon Kayaku Kabushiki Kaisha | タキサン類の高分子結合体 |
WO2009041570A1 (ja) * | 2007-09-28 | 2009-04-02 | Nippon Kayaku Kabushiki Kaisha | ステロイド類の高分子結合体 |
WO2009142326A1 (ja) * | 2008-05-23 | 2009-11-26 | ナノキャリア株式会社 | ドセタキセル高分子誘導体、並びにその製造方法及びその用途 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2754682A4 |
Also Published As
Publication number | Publication date |
---|---|
AU2012305405B2 (en) | 2016-01-14 |
TWI544012B (zh) | 2016-08-01 |
ES2635117T3 (es) | 2017-10-02 |
BR112014005452B1 (pt) | 2021-03-16 |
BR112014005452A2 (pt) | 2017-03-21 |
KR20140068954A (ko) | 2014-06-09 |
US9346923B2 (en) | 2016-05-24 |
EP2754682B1 (en) | 2017-06-07 |
JP5711378B2 (ja) | 2015-04-30 |
JPWO2013035641A1 (ja) | 2015-03-23 |
TW201319129A (zh) | 2013-05-16 |
CN103874722B (zh) | 2016-06-29 |
EP2754682A1 (en) | 2014-07-16 |
PT2754682T (pt) | 2017-08-29 |
CN103874722A (zh) | 2014-06-18 |
EP2754682A4 (en) | 2015-04-08 |
CA2847114C (en) | 2018-08-21 |
US20140288244A1 (en) | 2014-09-25 |
RU2623426C2 (ru) | 2017-06-26 |
KR101849142B1 (ko) | 2018-04-16 |
RU2014114264A (ru) | 2015-10-20 |
CA2847114A1 (en) | 2013-03-14 |
AU2012305405A1 (en) | 2014-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5711378B2 (ja) | ブロック共重合体の製造方法 | |
JP5369137B2 (ja) | 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤 | |
USRE46190E1 (en) | High-molecular weight conjugate of steroids | |
CN102159250A (zh) | 多臂的聚合烷酸酯偶联物 | |
EP3078699A1 (en) | Multi-arm polyethylene glycol-nitrine derivative | |
US20240150379A1 (en) | Boronated Multifunctional Targeting Drug Conjugates, Their Uses and Methods for Their Preparation | |
US20220024966A1 (en) | Functionalized bile acids for therapeutic and material applications | |
KR100771100B1 (ko) | 고순도의 메톡시폴리에틸렌글리콜에틸말레이미드의제조방법 | |
US11912709B2 (en) | Temozolomide compounds, polymers prepared therefrom, and method of treating a disease | |
KR20220134528A (ko) | 치료 나노입자의 합성을 위한 방법 및 조성물 | |
CN102336904B (zh) | 一种喜树碱及其衍生物的多价peg修饰物及其用途 | |
JP6817956B2 (ja) | 新規なグルタミン酸誘導体とブロック共重合体を含有する組成物及びその用途 | |
KR102138415B1 (ko) | 신규 peg 유도체 | |
Fattahi et al. | Preparation and physicochemical characterization of camptothecin conjugated poly amino ester–methyl ether poly ethylene glycol copolymer | |
CN104650344A (zh) | 一种peg化伊立替康的轭合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12830758 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013532568 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2012830758 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2847114 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20147006350 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2014114264 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14241924 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2012305405 Country of ref document: AU Date of ref document: 20120831 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014005452 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014005452 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140310 |